Banque Cantonale Vaudoise Takes Position in Cencora, Inc. (NYSE:COR)

Banque Cantonale Vaudoise bought a new position in shares of Cencora, Inc. (NYSE:COR - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The firm bought 12,734 shares of the company's stock, valued at approximately $3,541,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in COR. New Age Alpha Advisors LLC increased its position in Cencora by 2,538.1% in the 4th quarter. New Age Alpha Advisors LLC now owns 3,113 shares of the company's stock valued at $699,000 after acquiring an additional 2,995 shares in the last quarter. Pictet Asset Management Holding SA boosted its stake in shares of Cencora by 26.1% in the 4th quarter. Pictet Asset Management Holding SA now owns 126,017 shares of the company's stock valued at $28,314,000 after purchasing an additional 26,051 shares during the last quarter. Schroder Investment Management Group bought a new position in shares of Cencora in the 4th quarter valued at about $41,378,000. O Shaughnessy Asset Management LLC boosted its stake in shares of Cencora by 16.7% in the 4th quarter. O Shaughnessy Asset Management LLC now owns 52,965 shares of the company's stock valued at $11,900,000 after purchasing an additional 7,597 shares during the last quarter. Finally, B. Metzler seel. Sohn & Co. AG boosted its stake in shares of Cencora by 0.9% in the 4th quarter. B. Metzler seel. Sohn & Co. AG now owns 7,389 shares of the company's stock valued at $1,660,000 after purchasing an additional 69 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company's stock.

Wall Street Analyst Weigh In

COR has been the topic of several recent research reports. Wells Fargo & Company raised shares of Cencora from an "equal weight" rating to an "overweight" rating and raised their target price for the company from $274.00 to $337.00 in a research note on Tuesday, June 3rd. Robert W. Baird lifted their price objective on shares of Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a research note on Thursday, May 8th. UBS Group lifted their price objective on shares of Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Morgan Stanley set a $330.00 price objective on shares of Cencora and gave the stock an "equal weight" rating in a research note on Wednesday, July 16th. Finally, Citigroup lifted their price objective on shares of Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. Three equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, Cencora currently has an average rating of "Moderate Buy" and a consensus target price of $309.83.

Insider Buying and Selling at Cencora

In related news, Chairman Steven H. Collis sold 14,579 shares of the business's stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $292.62, for a total transaction of $4,266,106.98. Following the transaction, the chairman directly owned 311,913 shares in the company, valued at approximately $91,271,982.06. The trade was a 4.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Robert P. Mauch sold 4,968 shares of the company's stock in a transaction on Friday, July 18th. The shares were sold at an average price of $294.11, for a total transaction of $1,461,138.48. Following the completion of the transaction, the chief executive officer owned 42,351 shares in the company, valued at approximately $12,455,852.61. This represents a 10.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 34,125 shares of company stock valued at $9,993,789 in the last 90 days. 10.80% of the stock is currently owned by corporate insiders.

Cencora Stock Up 0.8%

COR stock traded up $2.23 during mid-day trading on Friday, hitting $288.31. 1,140,211 shares of the company were exchanged, compared to its average volume of 1,571,950. The company has a debt-to-equity ratio of 6.01, a quick ratio of 0.52 and a current ratio of 0.87. The firm has a market cap of $55.88 billion, a P/E ratio of 33.45, a P/E/G ratio of 1.45 and a beta of 0.57. The firm's 50 day simple moving average is $293.13 and its 200 day simple moving average is $275.35. Cencora, Inc. has a 1-year low of $218.65 and a 1-year high of $309.35.

Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, topping the consensus estimate of $4.07 by $0.35. Cencora had a net margin of 0.55% and a return on equity of 344.71%. The business had revenue of $75.50 billion during the quarter, compared to analysts' expectations of $75.41 billion. During the same quarter in the prior year, the company posted $3.80 earnings per share. The firm's revenue was up 10.3% on a year-over-year basis. On average, sell-side analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, June 2nd. Investors of record on Friday, May 16th were issued a dividend of $0.55 per share. The ex-dividend date was Friday, May 16th. This represents a $2.20 annualized dividend and a yield of 0.8%. Cencora's dividend payout ratio is presently 25.52%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.